Closing soon

Jerry - Radiopharmaceuticals *SOLE SOURCE*

Description: Lu-177 vipivotide tetraxetan (PLUVICTO) is a radioligand therapeutic agent to perform the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive and metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor pathway inhibitor (ARPI) therapy and are considered appropriate to delay taxane-based chemotherapy or have received prior taxane-based chemotherapy. See attached file.

Released
Aug 12, 2026
Closes
Aug 18, 2026(1 days left)

Files

Original attachments and procurement documents tied to this bid.

Federal RFP files are for Starbridge customers only.

You can request RFP files from all other buyer types for free on this site.

See your top accountsScan your site in seconds. Starbridge identifies your ICP and surfaces emerging opportunities from board meetings, job changes, new grants, contract expirations, RFPs, and more.
See your top 10 accounts